4D Pharma Joins The SPAC Trend To Fund Its Keytruda-Boosting Biotherapeutic
A Platform To Attract More Investors
Executive Summary
The Leeds, UK-based company is looking to the alternative route to the US stock market to fund its live biotherapeutics platform.
You may also be interested in...
IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports